View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types

Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types

Saturday, May 30, 2020

Live Webcast!

Program: 7:30 - 9:30 PM ET

Exploring Future Applications of HER2/3-Targeted Therapies: Program Overview

For over 20 years, trastuzumab has been the foundation of therapy for patients with HER2+ breast cancer, and now novel biosimilars and antibody-drug conjugates have emerged for continual improvement of treatment outcomes for these patients. HER2 and HER3 amplification has been increasingly recognized as a frequent abnormality in not only gastric cancer, but also gastroesophageal and colorectal cancers, enabling oncologists to administer HER2/3-targeted therapies to these patients as well. HER2 amplification and overexpression, however, are much more heterogeneous in these tumor types compared to breast cancer, with incomplete membrane staining resulting in the need for an exclusive scoring and interpretation system for gastrointestinal tumor samples. While EGFR, another receptor related to HER2, has long been a target successfully treated in patients with non–small cell lung cancer, novel anti-HER2 agents have emerged to combat tumor resistance.

Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types is a CME-certified virtual symposium, ancillary to the annual meeting in Chicago, to be held on Saturday, May 30, 2020. This educational activity will help physicians assess the latest available data on HER2/3-targeted treatment strategies for the care of patients with breast, gastrointestinal, and lung cancers. Renowned experts will discuss the rationale for targeting HER2 and HER3 overexpression in multiple tumor types and how these strategies have evolved in recent years. They will also share best practices for incorporating key data from landmark clinical trials of HER2-positive cancers into the everyday clinic, as well as review emerging novel anti-HER2/3 agents under investigation. In this time of innovative cancer therapeutics, we look forward to you joining us to learn how to bring the latest HER2/3-targeted treatment strategies to your patients living with cancer.

Benefits of Participating in This Live CME Event, Hosted by PER®

  • Gain awareness of the clinical trials evaluating current and emerging HER2/3-targeted therapies for treatment of breast, lung, and gastrointestinal cancers that may affect your practice in the future
  • Understand optimal HER2 testing methods for different tumor types
  • Learn how the experts and your peers are managing challenging cases across multiple HER2-positive cancer types
  • Ask the experts about best practices for mitigating adverse events related to HER2/3-targeted therapies

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Target Audience: HCPs Who Treat Cancer

This educational program is directed toward medical oncologists, pathologists, radiation oncologists, and surgical oncologists. Other attendees of the annual meeting who have an interest in the treatment of cancer such as nurses, physician assistants, fellows, and residents are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the rationale supporting the role of HER2/3 targeted therapies across multiple tumor types
  • Outline HER2 testing strategies across multiple tumor types
  • Review recent clinical trial data and ongoing clinical trial evaluating HER2/3 targeted strategies across multiple cancers
  • Discuss strategies for integrating HER2/3 targeted therapies into clinical practice for treatment of multiple tumor types, including mitigation of treatment-associated adverse events

Program Chair

Sara A. Hurvitz, MD
Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Director, Breast Cancer Clinical Trials Program
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
David Geffen School of Medicine at UCLA
Santa Monica, CA


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By